Corticosteroid Use in a Prospective, Community-Based Cohort of Newly Diagnosed Inflammatory Bowel Disease Patients

Digestive Diseases and Sciences

Volumn 61, Issue 6, 2016, Pages 1635-1640

  Shapiro, Jason M ^a,b   Hagin, Sarah E ^a,b   Shah, Samir A ^b,c   Bright, Renee ^a   Law, Meaghan ^a   Moniz, Heather ^a   Giacalone, Julie ^d   Jackvony, Taylor ^a   Taleban, Sasha ^a,b   Samad, Zahid ^e   Merrick, Marjorie ^f   Sands, Bruce E ^d   LeLeiko, Neal S ^a,b  

^a RHODE ISLAND HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

^c Gastroenterology Associates Inc   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^f Crohn's and Colitis Foundation of America   (United States)

Author keywords

Corticosteroids; Crohn s disease; Inflammatory bowel disease; Surgical resections; Ulcerative colitis

Indexed keywords

CORTICOSTEROID; PREDNISOLONE; PREDNISONE;

ADULT; ARTICLE; COHORT ANALYSIS; CROHN DISEASE; DISEASE ACTIVITY; DRUG USE; FEMALE; HOSPITALIZATION; HUMAN; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; ULCERATIVE COLITIS; ADOLESCENT; CHILD; COLITIS, ULCERATIVE; MIDDLE AGED;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; CHILD; COHORT STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 84952690367     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-4010-4     Document Type: Article

References (18)

1. Truelove SC, Witt LJ. Cortisone in ulcerative colitis. Final report on a therapeutic trial. BMJ. 1955;2:1041–1048.
2. Munkholm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in Crohn’s disease. Gut. 1994;35:360.
3. Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255.
4. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn’s disease with 6-mercaptopurine. N Engl J Med. 1980;302:981–987.
5. Ho GT, Chiam P, Drummond H, et al. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther. 2006;24:319–330.
6. Van Dullemen HM, Van Deventer JH, Hommes DW, et al. Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995;109:129–135.
7. Tung J, Loftus E, Freese DK, et al. A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis. 2006;12:1093–1100.
8. Jakobsen C, Munkholm P, Paerregaard A, et al. Steroid dependency and pediatric inflammatory bowel disease in the era of immunomodulators—a population based study. Inflamm Bowel Dis. 2011;17:1731.
9. Krupoves A, Mack D, Seidman EG, et al. Immediate and longterm outcomes of corticosteroid therapy in pediatric Crohn’s disease patients. Inflamm Bowel Dis. 2011;17:954–962.
10. Jakobsen C, Bartek J, Wewer V, et al. Differences in phenotype and disease course in adult and paediatric inflammatory bowel disease—a population-based study. Aliment Pharmacol Ther. 2011;34:1217–1224.
11. Sands BE, LeLeiko NS, Shah S, et al. OSCCAR: ocean state Crohn’s and colitis area registry. Med Health RI. 2009;92:82–85.
12. NIDDK IBD Genetics Consortium Phenotype Operating Manual. 2006. http://info.med.yale.edu/intmed/ibdgc/resources/docs/Phenotyping_Manual_5-10-2006.pdf.
13. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749–753.
14. Vind I, Riis L, Jess T. Increasing incidence of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003–2005: a population-based study from the Danish Crohn Colitis Database. Am J Gastroenterol. 2006;101:1274–1282.
15. Rungoe C, Langholz E, Andersson M, et al. Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979–2011. Gut. 2014;63:1607–1616.
16. Eshuis EJ, Peters CP, van Bodegraven AA, et al. Ten years of infliximab for Crohn’s disease: outcome in 469 patients from 2 tertiary referral centers. Inflamm Bowel Dis. 2013;19:1622–1630.
17. Schaefer ME, Machan JT, Kawatu D, et al. Factors that determine risk for surgery in pediatric patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2010;8:789–794.
18. Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, et al. Surgery in a population-based cohort of Crohn’s disease from Olmstead County, Minnesota (1970–2004). Am J Gastroenterol. 2012;107:1693–1701.